/
Other
NSCLC
161
Pipeline Programs↗
184
Active Trials↗
104
Companies Involved↗
NSCLC is a highly competitive landscape with 161 programs across 104 companies. The most active players are Suzhou Suncadia Biopharmaceuticals Co., Ltd., Novartis, Allist Pharmaceuticals, Inc.. 27 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical17
Phase 130
Phase 287
Phase 327
Approved
No programs
Analysis
Modality Breakdown
83%
Small molecule
125 of 150 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 150 classified programs, each share of the total. Modality classified for 96% of 161 pipeline programs.
Analysis
Trial Status
454
clinical trials
Completed110 · 24%
Recruiting96 · 21%
Unknown status96 · 21%
Not yet recruiting47 · 10%
Terminated43 · 9%
Active, not recruiting40 · 9%
Other22 · 5%
Clinical Trials
Trial Activity
454 trials
An Open-label, Single-center Study to Evaluate the Dose Escalation and Cohort Expansion of YSCH-01 in Subjects With Pulmonary Metastasis of Advanced Solid Tumors and Advanced Non-small Cell Lung Cancer by Nebulized Inhalation Administration
Recruiting·CCancer Institute and Hospital, Chinese Academy of Medical Sciences·Phase 1·NCT07793500·36 enrolled
Page 1 of 31
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)